On August 19, 2025, lawyer Xu Feng from Shanghai Jiucheng Law Firm filed another investor compensation case against Guizhou Bailing Group Pharmaceutical Co.,Ltd. (002424) with the Guiyang Intermediate People's Court for false statements.
The investor compensation case against Guizhou Bailing Group Pharmaceutical Co.,Ltd. represented by lawyer Xu Feng has been submitted to the court and is currently awaiting the court's next arrangements. The legal team continues to advance the filing of subsequent cases and is still accepting compensation commissions from additional investors.
On November 8, 2024, Guizhou Bailing Group Pharmaceutical Co.,Ltd. (002424) announced it received a "Case Filing Notice" from the China Securities Regulatory Commission (CSRC). Due to suspected violations of information disclosure laws and regulations, the CSRC decided to open a case against the company according to the Securities Law, Administrative Penalty Law, and other relevant regulations.
Xu Feng, director of Shanghai Jiucheng Law Firm, believes that based on current violation facts, investors who purchased Guizhou Bailing Group Pharmaceutical Co.,Ltd. shares between April 23, 2022, and April 30, 2024, and sold or still hold shares after April 30, 2024, may initiate compensation claims.
Additionally, on August 19, 2025, lawyer Xu Feng filed another investor compensation case against Orient Group Incorporation (600811) with the court.
Some of the Orient Group Incorporation investor compensation cases represented by lawyer Xu Feng have been accepted by the court and are currently awaiting the court's next arrangements. The legal team is also continuing to accept compensation commissions from additional investors.
On the evening of March 16, 2025, Orient Group Incorporation announced it received an "Administrative Penalty Pre-Notice" from the CSRC. Investigation revealed that from 2020 to 2023, Orient Group Incorporation engaged in long-term agricultural product financing trade and circular trading through artificially adding business links or fabricating business chains to maintain agricultural product trading market share, meet financing needs, and satisfy performance assessments. These false sales activities resulted in Orient Group Incorporation's annual reports from 2020 to 2023 inflating operating revenue by 3,896,546,638.75 yuan, 4,865,498,090.36 yuan, 6,542,641,212.14 yuan, and 824,804,130.07 yuan respectively, accounting for 25.20%, 32.05%, 50.44%, and 13.56% of disclosed operating revenue (before correction) for each period. Operating costs were inflated by 3,875,480,343.50 yuan, 4,844,256,749.59 yuan, 6,530,267,411.95 yuan, and 823,740,728.14 yuan respectively, accounting for 23.74%, 29.57%, 45.43%, and 11.45% of disclosed operating costs for each period. Orient Group Incorporation's annual reports from 2020 to 2023 contained false records.
Xu Feng, director of Shanghai Jiucheng Law Firm, believes that investors who purchased Orient Group Incorporation shares between April 30, 2021, and June 22, 2024, and sold or still hold shares after June 22, 2024, may currently initiate compensation claims.
On July 25, 2025, Orient Group Incorporation issued an announcement regarding the termination of pre-reorganization and creditor application for bankruptcy liquidation, reminding investors to pay attention.
(This article was contributed by Xu Feng, director of Shanghai Jiucheng Law Firm. Xu Feng has been practicing law since 2008, with services covering compensation representation in securities fraud areas including false statements, insider trading, and market manipulation. Over more than ten years, he has represented investor cases for nearly 200 stocks that have won or reached settlement compensation, and is simultaneously representing compensation cases for nearly 300 stocks within the statute of limitations, some of which have also achieved successful precedents and settlement compensation. Practice License Number: 13101200810965495)
Comments